| 3101 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
54 |
| 3102 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
63 |
| 3103 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
54 |
| 3104 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
71 |
| 3105 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
67 |
| 3106 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia, Type 0 (Cmml-0)
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
64 |
| 3107 |
Apheresis |
Allogeneic
|
Chronic Neutrophilic Leukemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
66 |
| 3108 |
Apheresis |
Allogeneic
|
Chronic Neutrophilic Leukemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
72 |
| 3109 |
Apheresis |
Allogeneic
|
Combined Immunodeficiency Syndrome With Hyper-Igm
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
6 |
| 3110 |
Apheresis |
Allogeneic
|
Congenital Dyserythropoietic Anemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
2 |
| 3111 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
68 |
| 3112 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
65 |
| 3113 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
69 |
| 3114 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
50 |
| 3115 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
56 |
| 3116 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
65 |
| 3117 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
47 |
| 3118 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma – Relapse
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
66 |
| 3119 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma With Cerebral Acute Lymphoblastic Leukemia
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
66 |
| 3120 |
Apheresis |
Autologous
|
Germ Cell Tumor
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
39 |
| 3121 |
Apheresis |
Autologous
|
Germ Cell Tumor
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
33 |
| 3122 |
Apheresis |
Allogeneic
|
Hemophagocytic Lymphohistiocytosis (Hlh)
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
12 |
| 3123 |
Apheresis |
Allogeneic
|
Hemophagocytic Lymphohistiocytosis (Hlh)
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
21 |
| 3124 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
26 |
| 3125 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
31 |
| 3126 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
53 |
| 3127 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
25 |
| 3128 |
Apheresis |
Autologous
|
Hodgkin Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
67 |
| 3129 |
Apheresis |
Autologous
|
Hodgkin Lymphoma-Relapse
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
69 |
| 3130 |
Apheresis |
Autologous
|
Hodgkin Lymphoma-Relapse
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
48 |
| 3131 |
Apheresis |
Allogeneic
|
Hypoplastic Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
26 |
| 3132 |
Apheresis |
Allogeneic
|
Immunodeficiency
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
3 |
| 3133 |
Apheresis |
Allogeneic
|
Juvenile Myelomonocytic Leukemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
5 |
| 3134 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
64 |
| 3135 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
61 |
| 3136 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
52 |
| 3137 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
44 |
| 3138 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
53 |
| 3139 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
49 |
| 3140 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
64 |
| 3141 |
Apheresis |
Allogeneic
|
Mixed Phenotype Acute Leukemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
64 |
| 3142 |
Apheresis |
Autologous
|
Morbus Hodgkin
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
36 |
| 3143 |
Apheresis |
Autologous
|
Morbus Hodgkin
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
62 |
| 3144 |
Apheresis |
Autologous
|
Morbus Hodgkin-Relapse
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
63 |
| 3145 |
Apheresis |
Allogeneic
|
Mucopolysaccharidosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
2 |
| 3146 |
Apheresis |
Allogeneic
|
Mucopolysaccharidosis Type I
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
3 |
| 3147 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
58 |
| 3148 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
53 |
| 3149 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
57 |
| 3150 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
64 |
| 3151 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
50 |
| 3152 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
67 |
| 3153 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
55 |
| 3154 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
73 |
| 3155 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
63 |
| 3156 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
65 |
| 3157 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
58 |
| 3158 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
37 |
| 3159 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
47 |
| 3160 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
68 |
| 3161 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
53 |
| 3162 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
60 |
| 3163 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
60 |
| 3164 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
47 |
| 3165 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
59 |
| 3166 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
64 |
| 3167 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
59 |
| 3168 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
52 |
| 3169 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
73 |
| 3170 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
68 |
| 3171 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
63 |
| 3172 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
66 |
| 3173 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
50 |
| 3174 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
69 |
| 3175 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
57 |
| 3176 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
55 |
| 3177 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
61 |
| 3178 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
64 |
| 3179 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
71 |
| 3180 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
61 |
| 3181 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
62 |
| 3182 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
60 |
| 3183 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
33 |
| 3184 |
Apheresis |
Allogeneic
|
Multiple Myeloma – Relapse
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
43 |
| 3185 |
Apheresis |
Autologous
|
Multiple Myeloma Angioimmunoblastic T-Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
62 |
| 3186 |
Apheresis |
Allogeneic
|
Mycosis Fungoides
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
64 |
| 3187 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
65 |
| 3188 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
69 |
| 3189 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
76 |
| 3190 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
45 |
| 3191 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
63 |
| 3192 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
72 |
| 3193 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
70 |
| 3194 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
45 |
| 3195 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
73 |
| 3196 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
21 |
| 3197 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
46 |
| 3198 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
64 |
| 3199 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
71 |
| 3200 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
49 |